文献速递肾移植

ASCENT干预措施改善肾脏等待名单登记可及性并减少种族不平等:一项随机实效性-实施性试验

The ASCENT Intervention to Improve Access and Reduce Racial Inequalities in Kidney Waitlisting: A Randomized, Effectiveness-Implementation Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-02-08

ASCENT研究为整群随机实效性-实施性试验,纳入655家等待名单登记率低的美国透析机构,评估多组分教育干预对等待名单登记及黑白种族差异的影响。干预组黑人患病患者1年等待名单登记比例从2.52%升至2.78%,而白人患者保持2.66%至2.69%;新发黑人患者从0.87%升至1.07%,白人患者从1.54%降至1.27%。结论认为干预可能通过减弱等待名单登记的种族差异,对新KAS政策的覆盖范围产生小幅扩展作用。

要点

  • 干预组黑人患病患者1年等待名单登记比例从2.52%升至2.78%,白人患者保持2.66%至2.69%。
  • 干预组新发黑人患者1年等待名单登记比例从0.87%升至1.07%,白人患者从1.54%降至1.27%。
  • 基线时干预组新发黑人患者较白人患者更不易进入等待名单(aOR 0.56,95%CI 0.35至0.92),干预1年后该差异减弱(aOR 0.84,95%CI 0.49至1.42)。

核心结论

  • ASCENT干预可能通过减弱美国低等待名单登记率透析机构中等待名单登记的种族差异,对新KAS政策的覆盖范围产生小幅扩展作用。

研究设计与样本

  • 整群随机、实效性-实施性、多水平试验,纳入655家等待名单登记率低的美国透析机构,随机接受ASCENT干预(绩效反馈报告、网络研讨会及员工和患者教育视频)或教育手册。
  • 共同主要结局为1年等待名单登记率及等待名单登记的种族差异,在现患和新发患者中报告绝对差异和相对差异。

主要发现

  • 56,332例现患患者中,对照机构患者1年等待名单登记率从2.72%降至2.56%,干预机构患者保持2.68%至2.75%。
  • 干预机构现患黑人患者等待名单登记比例从基线2.52%升至1年2.78%,白人患者保持2.66%至2.69%。
  • 干预机构新发黑人患者1年等待名单登记率从0.87%升至1.07%,白人患者从1.54%降至1.27%。
  • 基线时干预机构新发黑人患者较白人患者更不易进入等待名单(aOR 0.56,95%CI 0.35至0.92),干预1年后该种族差异减弱(aOR 0.84,95%CI 0.49至1.42)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The US kidney allocation system (KAS) changed in 2014, but dialysis facility staff (including nephrologists, social workers, nurse managers, and facility administrators) had low awareness of how this policy change could affect their patients' access to transplant. We assessed the effectiveness of a multicomponent and multilevel educational and outreach intervention targeting US dialysis facilities with low waitlisting, with a goal of increasing waitlisting and reducing Black versus White racial disparities in waitlisting. METHODS: The Allocation System Changes for Equity in Kidney Transplantation (ASCENT) study was a cluster-randomized, pragmatic, multilevel, effectiveness-implementation trial including 655 US dialysis facilities with low waitlisting, randomized to receive either the ASCENT intervention (a performance feedback report, a webinar, and staff and patient educational videos) or an educational brochure. Absolute and relative differences in coprimary outcomes (1-year waitlisting and racial differences in waitlisting) were reported among incident and prevalent patients. RESULTS: Among 56,332 prevalent patients, 1-year waitlisting decreased for patients in control facilities (2.72%-2.56%) and remained the same for patients in intervention facilities (2.68%-2.75%). However, the proportion of prevalent Black patients waitlisted in the ASCENT interventions increased from baseline to 1 year (2.52%-2.78%), whereas it remained the same for White patients in the ASCENT intervention facilities (2.66%-2.69%). Among incident patients in ASCENT facilities, 1-year waitlisting increased among Black patients (from 0.87% to 1.07%) but declined among White patients (from 1.54% to 1.27%). Significant racial disparities in waitlisting were observed at baseline, with incident Black patients in ASCENT facilities less likely to waitlist compared with White patients (adjusted odds ratio [aOR], 0.56; 95% confidence interval [CI], 0.35 to 0.92), but 1 year after the intervention, this racial disparity was attenuated (aOR, 0.84; 95% CI, 0.49 to 1.42). CONCLUSIONS: The ASCENT intervention may have a small effect on extending the reach of the new KAS policy by attenuating racial disparities in waitlisting among a population of US dialysis facilities with low waitlisting. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: National Institutes of Health ( NCT02879812 ). PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_03_08_CJN09760822.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Patzer RE, Zhang R, Buford J, et al. The ASCENT Intervention to Improve Access and Reduce Racial Inequalities in Kidney Waitlisting: A Randomized, Effectiveness-Implementation Trial. Clin J Am Soc Nephrol. 2023. PMID: 36764664. doi:10.2215/CJN.0000000000000071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。